Phaseline

Targets › PGLYRP4

PGLYRP4 (Peptidoglycan recognition protein 4): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.

Pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria. Has bactericidal activity towards Gram-positive bacteria. (UniProt, Q96LB8)

Open in Phaseline: the race on PGLYRP4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aura BiosciencesAU-011
anti-PGLYRP4 antibody-drug conjugate
PGLYRP4Phase 2Eye Cancer; Non-muscle-invasive Bladder CancerNov 2026

Conditions

Eye Cancer (1) Non-muscle-invasive Bladder Cancer (1)

Modalities

small molecule (1)

Companies

Aura Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.